59956-49-9

Upstream product

• 584-02-1 2-pentanol 
• 105-36-2 ethyl bromoacetate 
• 79-08-3 bromoacetic acid 

Downstream Products

• 1262515-92-3 3''-pentyl (3S,5R,αS)-3-[N-benzyl-N-(α-methylbenzyl)amino]-4-[2',2';-dimethyl-N(3')-tert-butoxycarbonyl-1',3'-oxazolidin-5'-yl]butanoate 
• 1262515-94-5 3'-pentyl (R,R)-3-(N-benzyloxycarbonylamino)-4-[N(3')-tert-butoxycarbonyl-2',2'-dimethyl-1',3-oxazolidin-5'-yl]butanoate 
• 181772-74-7 3''-pentyl (R,R,R)-3-[N-benzyl-N-(α-methylbenzyl)amino]-4-[2',2';-dimethyl-N(3')-tert-butoxycarbonyl-1',3'-oxazolidin-5'-yl]butanoate 
• 1262515-99-0 [2-oxo-2-(3'-pentyloxy)ethyl]triphenylphosphonium bromide 

Relevant academic research and scientific papers

Asymmetric syntheses of (+)-negamycin, (+)-3-epi-negamycin and sperabillin C via lithium amide conjugate addition

The chemo- and enantioselective reduction of ethyl 4-chloroacetoacetate and the diastereoselective conjugate addition of enantiopure lithium N-benzyl-N-(α-methylbenzyl)amide to an α,β-unsaturated ester have been used as the key steps in the total asymmetric syntheses of (+)-negamycin (in 13 steps and 24% overall yield), (+)-3-epi-negamycin (in 13 steps and 10% overall yield) and sperabillin C (in 17 steps and 13% overall yield) from commercially available starting materials.